Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Radiotherapy for Elderly Esophageal Carcinoma
NCT00524121Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2006
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in esophageal carcinoma, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Overall Survival at 5 years. Started Mar 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT00524121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00524121.